During the last session, ProQR Therapeutics N.V (NASDAQ:PRQR)’s traded shares were 1.35 million, with the beta value of the company hitting 0.06. At the end of the trading day, the stock’s price was $2.04, reflecting an intraday gain of 0.99% or $0.02. The 52-week high for the PRQR share is $4.62, that puts it down -126.47 from that peak though still a striking 21.08% gain since the share price plummeted to a 52-week low of $1.61. The company’s market capitalization is $210.53M, and the average trade volume was 405.49K shares over the past three months.
ProQR Therapeutics N.V (PRQR) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.29. PRQR has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it.
ProQR Therapeutics N.V (NASDAQ:PRQR) trade information
ProQR Therapeutics N.V (PRQR) registered a 0.99% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 0.99% in intraday trading to $2.04, hitting a weekly high. The stock’s 5-day price performance is -15.00%, and it has moved by -9.33% in 30 days. Based on these gigs, the overall price performance for the year is 3.03%.
The consensus price target of analysts on Wall Street is $3.75, which implies an increase of 45.6% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 and $5 respectively. As a result, PRQR is trading at a discount of -145.1% off the target high and 1.96% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 21.74%. While earnings are projected to return 1.73% in 2025, the next five years will return -15.10% per annum.
PRQR Dividends
ProQR Therapeutics N.V is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 3.63 million shares, is of ADAGE CAPITAL PARTNERS GP, L.L.C.’s that is approximately 4.4394% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $6.02 million.
Also, the Mutual Funds coming in first place with the largest holdings of ProQR Therapeutics N.V (PRQR) shares are Delaware Group Equity Fds IV-Delaware Healthcare Fund and Fidelity Small Cap Growth Fund . Data provided on Dec 31, 2024 indicates that Delaware Group Equity Fds IV-Delaware Healthcare Fund owns about 620.0 shares. This amounts to just over 0.76 percent of the company’s overall shares, with a $1.26 million market value. The same data shows that the other fund manager holds slightly less at 600.19, or about 0.73% of the stock, which is worth about $1.22 million.
